Sep 12, 2019
We just used clinical trial data
regarding eculizumab in myasthenia gravis as an example of how to
critically appraise the literature, and in this week's
program...MORE data on the efficacy of eculizumab in another
neurological condition. This week on BrainWaves, the exciting
results of the PREVENT trial and the future treatment of NMO
Produced by James E. Siegler.
Special thanks to Dr. Olga Rosenveld Thon. Music courtesy of
Unheard Music Concepts, TRG Banks, and Aitua. Sound effects by Mike
Koenig and baby Sofia Joan Siegler. BrainWaves' podcasts and online
content are intended for medical education only and should not be
used for clinical decision making. Be sure to follow us on Twitter
@brainwavesaudio for the latest updates to the
- Pittock SJ, Lennon VA, McKeon A,
Mandrekar J, Weinshenker BG, Lucchinetti CF, O'Toole O and
Wingerchuk DM. Eculizumab in AQP4-IgG-positive relapsing
neuromyelitis optica spectrum disorders: an open-label pilot study.
The Lancet Neurology. 2013;12:554-62.
- Pittock SJ, Berthele A, Fujihara
K, Kim HJ, Levy M, Palace J, Nakashima I, Terzi M, Totolyan N,
Viswanathan S, Wang KC, Pace A, Fujita KP, Armstrong R and
Wingerchuk DM. Eculizumab in Aquaporin-4-Positive Neuromyelitis
Optica Spectrum Disorder. The New England journal of
- FDA News Release: FDA approved
first treatment for neuromyelitis optica spectrum disorder, a rare
autoimmune disease of the central nervous system. 27 June 2019.
Available online at
Accessed 30 Aug 2019.